Aquestive Therapeutics Inc (AQST) - Total Liabilities
Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) has total liabilities worth $175.18 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Aquestive Therapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Aquestive Therapeutics Inc - Total Liabilities Trend (2005–2025)
This chart illustrates how Aquestive Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Aquestive Therapeutics Inc total assets.
Aquestive Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aquestive Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thai Stanley Electric Public Company Limited
BK:STANLY
|
Thailand | ฿2.52 Billion |
|
Zhejiang Starry Pharm Co Ltd
SHG:603520
|
China | CN¥3.69 Billion |
|
SandRidge Energy Inc
NYSE:SD
|
USA | $126.16 Million |
|
Asante Gold Corporation
F:1A9
|
Germany | €855.73 Million |
|
Fineos Corporation Holdings Plc
AU:FCL
|
Australia | AU$33.29 Million |
|
Bankwell Financial Group Inc
NASDAQ:BWFG
|
USA | $3.15 Billion |
|
Universal Cables Limited
NSE:UNIVCABLES
|
India | Rs24.32 Billion |
|
Jiangsu Hanvo Safety Product Co. Ltd.
SHE:300952
|
China | CN¥1.19 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Aquestive Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Aquestive Therapeutics Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aquestive Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual total liabilities of Aquestive Therapeutics Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $194.09 Million | +20.12% |
| 2024-12-31 | $161.58 Million | -1.42% |
| 2023-12-31 | $163.91 Million | -6.67% |
| 2022-12-31 | $175.62 Million | +21.85% |
| 2021-12-31 | $144.13 Million | +29.40% |
| 2020-12-31 | $111.38 Million | +31.65% |
| 2019-12-31 | $84.60 Million | +10.20% |
| 2018-12-31 | $76.77 Million | +10.29% |
| 2017-12-31 | $69.61 Million | +22.20% |
| 2016-12-31 | $56.97 Million | +2873.12% |
| 2006-12-31 | $1.92 Million | -74.92% |
| 2005-12-31 | $7.64 Million | -- |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more